PD L1 News and Research

RSS

Immunotherapy breakthrough: Pembrolizumab extends time to recurrence in aggressive bladder cancer

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option.

27 Jan 2024

Lung cancer prediction using biomarkers based on bronchoalveolar fluid microbiomes

The lung microbiomes of patients with benign and malignant pulmonary diseases.

23 Jan 2024

High-resolution map of the neuroblastoma immune landscape points to new target for immunotherapy

A detailed 'atlas' of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for Pediatric Oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells.

4 Jan 2024

Researchers identify the culprit responsible for harmful inflammation in certain muscular disorders

Inflammation is an important part of the body's defenses, eliminating threats and repairing damage. When the immune system is overactivated, though, it can turn from friend to foe.

14 Dec 2023

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Simple bean diet intervention demonstrates significant prebiotic effects

The impact of incorporating canned navy beans into the regular diet for eight weeks.

5 Dec 2023

Research paves way for clinical trials of existing drugs for brain metastasis

The largest review of papers for brain cancer that has spread from the lungs has found abnormalities in the brain cancer and for which licensed drugs could be clinically trialled to find out if they could treat the disease.

29 Nov 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

AmoyDx and CST Expand Existing Partnership for the Development of Companion Diagnostics (CDx) to Support Precision Oncology

Cell Signaling Technology (CST), a life science biotechnology company and leading provider of antibodies, kits, and services, and Amoy Diagnostics Co., Ltd. (AmoyDx), a China-based innovative molecular diagnostics company in the field of precision oncology, announced today the expansion of their ongoing partnership for companion diagnostic (CDx) development in China.

From Cell Signaling Technology 23 Nov 2023

New approach to stem cell transplantation may overcome immune rejection

Cell and organ transplants can be lifesaving, but patients often encounter long waiting lists due to the shortage of suitable donors.

22 Nov 2023

Combined application of therapeutic viruses and nanomaterials to revolutionize cancer therapy

Using oncolytic viruses (OVs) in combination with nanomaterials as a novel approach to cancer treatment.

22 Nov 2023

Immunotherapy drug is safe and may benefit overall survival for patients with advanced NSCLC

For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new eClinicalMedicine study by UPMC Hillman Cancer Center researchers.

21 Nov 2023

Novel urine-based prognostic model promises to transform bladder cancer treatment

In a study published in the journal Genes & Diseases, researchers from Fudan University, have developed a novel urine-based prognostic model that promises to transform the management and treatment of bladder cancer.

21 Nov 2023

HIF-2α inhibitor belzutifan significantly reduces progression of clear cell renal cell carcinoma

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

24 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

New method uses extracellular vesicles to enhance immunotherapy responses in glioblastoma

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a new method for using extracellular vesicles to enhance responses to immunotherapy in glioblastoma, potentially opening the door for wider use of engineered messenger RNA (mRNA) for cancer therapy.

19 Oct 2023

Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics

Antiverse Ltd (Antiverse) and GlobalBio, Inc. (GlobalBio) today announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.

From Antiverse 16 Oct 2023

Researchers discover a vulnerability in immunotherapy-resistant triple-negative breast cancer

Researchers at Vanderbilt-Ingram Cancer Center have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

5 Oct 2023

Breakthrough study shows immunotherapy can help prevent bladder cancer recurrence

The Alliance for Clinical Trials in Oncology today announced that the Alliance Data and Safety Monitoring Board (DSMB) determined that the phase III AMBASSADOR (A031501) trial met one of its dual primary endpoints of disease-free survival (DFS) for the adjuvant treatment of patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced urothelial carcinoma.